BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Keytruda is currently indicated in a variety of cancers ... on our successful ongoing collaboration on BNT327/PM8002 and ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... The trials will assess the bispecific antibody in combination ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

including antibody-drug conjugates from its existing portfolio. It said it saw BNT327’s dual-target approach as a significant ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

SpiritMedia.US, a leading international book publishing and marketing company, celebrates the release of The Pyramid Principle by John Vallely with Paul Weissenstein on Tuesday9, 2024. The book shares ...

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...